Rivastigmine Patch, Extended Release
NDC Package 70771-1949-7

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Rivastigmine patches is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. This formulation utilizes a patch, extended release delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1949 and is authorized under FDA application ANDA206318.

Identification & Billing

NDC Package Code
70771-1949-7
Package Description
30 POUCH in 1 CARTON / 24 h in 1 POUCH (70771-1949-1)
Product Code
11-Digit Billing Format
70771194907
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Rivastigmine
Non-Proprietary Name
Rivastigmine
Substance Name
Rivastigmine
Dosage Form
Patch, Extended Release - A drug delivery system in the form of a patch that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form).
Administration Route
Transdermal - Administration through the dermal layer of the skin to the systemic circulation by diffusion.
Active Ingredient(s)
Usage Information
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA206318
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-06-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70771-1949-7 identifies a specific commercial package of 30 pouch in 1 carton / 24 h in 1 pouch (70771-1949-1) of Rivastigmine, a human prescription drug labeled by Zydus Lifesciences Limited. This patch, extended release is formulated for transdermal use and contains rivastigmine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on March 06, 2019. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771194907. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70771-1949-7
11-Digit CMS (5-4-2)
70771-1949-07

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.